Your browser doesn't support javascript.
loading
Individual lifetime benefit from low-dose colchicine in patients with chronic coronary artery disease.
Burger, Pascal M; Dorresteijn, Jannick A N; Fiolet, Aernoud T L; Koudstaal, Stefan; Eikelboom, John W; Nidorf, Stefan M; Thompson, Peter L; Cornel, Jan H; Budgeon, Charley A; Westendorp, Iris C D; Beelen, Driek P W; Martens, Fabrice M A C; Steg, Philippe Gabriel; Asselbergs, Folkert W; Cramer, Maarten J; Teraa, Martin; Bhatt, Deepak L; Visseren, Frank L J; Mosterd, Arend.
Affiliation
  • Burger PM; Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Dorresteijn JAN; Department of Vascular Medicine, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Fiolet ATL; Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Koudstaal S; Dutch Cardiovascular Research Network (WCN), Moreelsepark 1, 3511 EP Utrecht, The Netherlands.
  • Eikelboom JW; Dutch Cardiovascular Research Network (WCN), Moreelsepark 1, 3511 EP Utrecht, The Netherlands.
  • Nidorf SM; Department of Cardiology, Green Heart Hospital, Gouda, The Netherlands.
  • Thompson PL; Department of Medicine, McMaster University, Hamilton, Canada.
  • Cornel JH; Department of Cardiology, GenesisCare Western Australia, Perth, Australia.
  • Budgeon CA; Heart Research Institute of Western Australia, Perth, Australia.
  • Westendorp ICD; Department of Cardiology, GenesisCare Western Australia, Perth, Australia.
  • Beelen DPW; Heart Research Institute of Western Australia, Perth, Australia.
  • Martens FMAC; Dutch Cardiovascular Research Network (WCN), Moreelsepark 1, 3511 EP Utrecht, The Netherlands.
  • Steg PG; Department of Cardiology, Radboud University Medical Centre, Nijmegen, The Netherlands.
  • Asselbergs FW; School of Population and Global Health, University of Western Australia, Perth, Australia.
  • Cramer MJ; Department of Cardiology, Red Cross Hospital, Beverwijk, The Netherlands.
  • Teraa M; Department of Cardiology, IJsselland Hospital, Capelle aan den IJssel, The Netherlands.
  • Bhatt DL; Dutch Cardiovascular Research Network (WCN), Moreelsepark 1, 3511 EP Utrecht, The Netherlands.
  • Visseren FLJ; Department of Cardiology, Deventer Hospital, Deventer, The Netherlands.
  • Mosterd A; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat, Université de Paris, Paris, France.
Eur J Prev Cardiol ; 30(18): 1950-1962, 2023 12 21.
Article in En | MEDLINE | ID: mdl-37409348
The long-term benefits of treatment with low-dose colchicine were estimated for 36 642 individuals with coronary heart disease, and compared with those of lipid- and blood pressure­lowering therapy. On average, low-dose colchicine was estimated to lower the risk of cardiovascular disease in the next 10 years from 17.8 to 13.2% (a reduction of 4.6% points) and to afford 2.0 additional years of life without cardiovascular disease.Low-dose colchicine was estimated to be the most effective treatment in 49%, intensive blood pressure­lowering therapy in 28%, and intensive lipid-lowering therapy in 23% of patients.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Artery Disease / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Myocardial Infarction Type of study: Guideline / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Eur J Prev Cardiol Year: 2023 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Coronary Artery Disease / Hydroxymethylglutaryl-CoA Reductase Inhibitors / Myocardial Infarction Type of study: Guideline / Prognostic_studies Aspects: Patient_preference Limits: Humans Language: En Journal: Eur J Prev Cardiol Year: 2023 Document type: Article Affiliation country: Netherlands Country of publication: United kingdom